NCT04227431

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China

The Effect of Tresiba® (Insulin Degludec) in Type 2 Diabetes Patients in Real World Clinical Practice in China - Noninterventional, Retrospective Chart Review Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 938 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to collect information on how Tresiba® works in patients with type 2 diabetes in China. The study will be based on data already recorded in participants' medical records and no new tests or procedures are required as part of the study. This study does not affect participants' current diabetes treatment. The study will look at data recorded in participants' medical records for approximately the last year. After signing the informed consent form, no further activities will be required from the participants.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
OTHER	Insulin degludec	Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.

Timeline

• Start date: 2020-01-17
• Primary completion: 2021-07-17
• Completion: 2021-07-17
• First posted: 2020-01-13
• Last updated: 2024-03-20

Locations

56 sites across 1 country: China